Completed PHASE3 INTERVENTIONAL 1-arm NCT03525821

Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED) (KETAPED)

Intranasal Ketamine Use in the Management of Upper Limb's Fracture Reduction in Pediatric Emergencies

Sponsor: Fondation Lenval

Updated 8 times since 2018 Last updated: Oct 5, 2020 Started: Jul 5, 2018 Primary completion: Sep 13, 2020 Completion: Sep 13, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03525821, this PHASE3 trial focuses on Fractures, Closed and remains completed. Sponsored by Fondation Lenval, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Mar 2020 — Nov 2020 [monthly]

Recruiting PHASE3

▶ Show 3 earlier versions

Aug 2019 — Mar 2020 [monthly]

Recruiting PHASE3
Aug 2018 — Aug 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Aug 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondation Lenval

Data source: Fondation Lenval

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nice, France